Reports
Reports
The radiopharmaceutical business is witnessing a high growth rate due to technological developments in nuclear medicine and increasing applications in targeted therapy and diagnostic imaging. Radiopharmaceuticals have been referred to as labeled medicine with radioisotopes employed for disease diagnosis or treatment, that is, oncology, cardiology, and neurology.
The growing demand for early disease diagnosis and personalized treatment and tailored drugs and hence growing interest to create innovative radiopharmaceuticals drives the demand.
.webp "Radiopharmaceuticals Market Revenue Growth (USD Bn)")
Market leaders are making R&D investments in the development of innovative products with better image accuracy and therapy. Heavy prevalence of chronic disease and an exploding population are also generating demand for radiopharmaceuticals. Collaboration among drug company research centers and approvals are also driving market growth.
Exorbitant production cost and strict regulatory environments are, however, retarding market growth. Overall, there is going to be huge expansion in radiopharmaceutical market and therefore an incredibly significant business to invest and expand in the health care sector.
Radiopharmaceuticals are chemical substances having specific properties to be combined with radioactive isotopes, and employed in nuclear medicine to diagnose and treat diseases. Agents function by playing a key role in imaging modalities, i.e., positron emission tomography (PET) and single-photon emission computed tomography (SPECT). They allow clinicians to visualize physiological processes on a real-time basis. By binding with specific organs or tissues, radiopharmaceuticals industry are capable of offering accurate information regarding disease, particularly in oncology, cardiology, and neurology.
Radiopharmaceuticals are used more in targeted therapy, wherein the cancer cells are targeted and fewer other cells are destroyed. More focus on personalized medicine and early detection of disease has given a new vigor to this discipline. New radiopharmaceuticals are thus synthesized and produced with increasing sensitivity in diagnosis and therapeutic effects. Radiopharmaceuticals are a medical revolution today, offering better patient care and more treatment.
| Attribute | Detail |
|---|---|
| Radiopharmaceuticals Market Drivers | Rising Burden of Cancer and Cardiovascular Diseases Technological Advancements in Radiotracer Development |
Increased worldwide incidence of cancer and cardiovascular disease (CVDs) is the biggest growth driver to the radiopharmaceutical market. Radiopharmaceuticals are employed in therapy as well as diagnosis in oncology (e.g., PET and SPECT imaging) and cardiology (e.g., myocardial perfusion scintigraphy).
For example, in 2022 alone, more than 20 million new cases of cancer were reported globally, as estimated by the International Agency for Research on Cancer (IARC) and are projected to increase over more than 28 million by the year 2040. Fluorodeoxyglucose (18F-FDG) is among the most frequent radiopharmaceuticals used in PET scan staging and diagnosis of the other cancers like lung cancer, breast cancer, and colorectal cancer. Likewise, in cardiology, technetium-99m (Tc-99m) labeled agents are the gold standard for coronary artery disease (CAD) and myocardial perfusion imaging.
Growing demand for non-invasive diagnostic equipment is also causing industry growth. Conventional tissue biopsies are destructive and restrictive, while radiopharmaceutical imaging provides a real-time whole-body scan with high sensitivity. Curative radiopharmaceutical lutetium-177 (Lu-177) and iodine-131 (I-131) are gaining use for expanse prostate cancer and thyroid cancer treatments, respectively, hence fueling the industry.
With life expectancy also set to increase and lifestyle issues still maintaining the pace of NCDs (non-communicable disease), demand will be healthy in the forthcoming years for challenging and image-guided diagnosis-and consequently for radiopharmaceuticals.
Ongoing innovation in the chemistry of radiotracers and imaging equipment continuously reveals new fields for radiopharmaceuticals and expands the market exponentially. Emerging tracers are hitting molecular targets with remarkable precision, enabling individualized diagnosis and treatment, one of the top trends of precision medicine.
For instance, the identification of Ga-68 DOTATATE, a gallium tracer used in NET imaging, has improved diagnostic sensitivity as compared to earlier SPECT agents. A case in point is PSMA-targeted radiopharmaceuticals such as Ga-68 PSMA-11 and Lu-177 PSMA-617, which have revolutionized diagnosis and treatment of prostate cancer. Ga-68 PSMA-11 was approved by the FDA in 2020 and Lu-177 PSMA-617 in 2022, which shows how innovation is being translated into commercial approvals and application.
One of the key innovations is alpha-emitting radiopharmaceuticals with highly localized delivery of very high doses of radiation with minimal off-target effect. Actinium-225 (Ac-225) drugs are in early clinical development for a variety of tumors, speaking of strong pipeline.
Hybrid imaging technologies such as PET/CT and PET/MRI also expanded the applications of radiopharmaceuticals by providing sensitive functional and anatomical information in a single session. These platforms require highly selective radiotracers, and this has fueled R&D expenditures by pharmaceutical companies and universities.
Therefore, advances in instrumentation, target identification, and radiochemistry not only increase the efficacy of diagnosis but also enlarge the horizon for clinical utility of radiopharmaceuticals, thereby acting as a key driver to the growth of the market.
Diagnostics radioisotopes are leading the radiopharmaceuticals market. Their biggest strength is their inherent utility in non-invasive imaging modalities such as PET and SPECT, enabling proper visualization of physiological functions and resulting in early disease diagnosis and accurate diagnosis. This aspect is highly critical when it comes to oncology, as early detection of tumors greatly increases the success rate of treatment.
Besides, rising cases of individuals with chronic diseases and an aging population have created a demand for efficient diagnostic tests. With shift toward preventive medicine, the demand for accurate diagnostic tests has never been higher. Diagnostic radioisotopes such as Technetium-99m and Fluorine-18 are chosen based on their longest available half-life and imaging properties, thereby being well-fitted for clinical use on a daily basis.
Additionally, process and technological innovation have expanded access and utilization of these radioisotopes, further extending their use. Approving processes and establishing manufacturing plants for radiopharmaceuticals have also contributed to the expansion in the market. With healthcare trending toward earlier diagnosis and more personal treatment methods, diagnostics radioisotopes will be the market leaders in radiopharmaceuticals, and heavily influence patient treatment and outcomes.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
North America holds the largest share of the radiopharmaceuticals market. Firstly, the region boasts a well-established healthcare infrastructure, which includes advanced medical facilities and a high level of investment in research and development. This environment does foster innovation and the rapid introduction of new radiopharmaceuticals, especially in targeted therapies and diagnostic imaging.
Secondly, the growing prevalence of chronic diseases such as cancer and cardiovascular conditions has driven demand for effective therapeutic and diagnostic solutions. North America’s aging population further amplifies this need, as older individuals are more likely to develop these conditions.
Additionally, the presence of major pharmaceutical companies and biotechnology firms in the region enables collaboration and enhances the development of new radiopharmaceuticals. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) have also been proactive in approving new products, thereby ascertaining that advancements reach the market efficiently.
Key players in the global radiopharmaceuticals market are investing in innovation, technological advancements, and forming alliances. Their objective is to improve the precision of testing, diversify their products, and gain a stronger market presence in order to be ahead of the curve in the evolving healthcare market.
Advanced Accelerator Applications, Bayer AG, Eli Lilly and Company, GE HealthCare, ITM Isotopen Technologien München AG, Jubilant Pharma Limited, Lantheus Holdings, Inc., Nihon Medi-Physics, Siemens Healthineers AG, Telix Pharmaceuticals are some of the leading key players.
Each of these players has been profiled in the radiopharmaceuticals market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Size in 2024 | US$ 6.6 Bn |
| Forecast Value in 2035 | US$ 14.6 Bn |
| CAGR | 7.6% |
| Forecast Period | 2025-2035 |
| Historical Data Available for | 2020-2023 |
| Quantitative Units | US$ Bn |
| Radiopharmaceuticals Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 6.6 Bn in 2024.
It is projected to cross US$ 14.6 Bn by the end of 2035.
Rising burden of cancer and cardiovascular diseases and technological advancements in radiotracer development.
It is anticipated to grow at a CAGR of 7.6% from 2025 to 2035.
North America is expected to account for the largest share from 2025 to 2035.
Advanced Accelerator Applications, Bayer AG, Eli Lilly and Company, GE Healthcare, ITM Isotopen Technologien München AG, Jubilant Pharma Limited, Lantheus Holdings, Inc., Nihon Medi-Physics, Siemens Healthineers AG, Telix Pharmaceuticals and Others.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Radiopharmaceuticals Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Radiopharmaceuticals Market Analysis and Forecast, 2020 to 2035
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. FDA Approved Radiopharmaceuticals Products
5.2. Epidemiology of Major Diseases
5.3. Reimbursement Scenario by key Countries/Regions
5.4. Pricing Analysis
5.5. Pipeline Analysis
5.6. Technological Advancements & Development
5.7. Insights on Pioneering Targeted in Radiotherapy
5.8. Regulatory Scenario by Country/Regions
5.9. Key Industry Events (Product Launch, Key Mergers and Acquisitions, etc.)
5.10. Number of Radiotherapy Centers: Major Country
6. Global Radiopharmaceuticals Market Analysis and Forecast, by Radioisotopes
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Radioisotopes, 2020 to 2035
6.3.1. Diagnostics
6.3.1.1. Fluorine-18 (F-18)
6.3.1.1.1. Fludeoxyglucose (FDG)
6.3.1.1.2. Sodium Fluoride
6.3.1.1.3. Flucicovine
6.3.1.1.4. Florbetapir
6.3.1.1.5. Florbetaben
6.3.1.1.6. Others
6.3.1.2. Gallium-68 (Ga-68)
6.3.1.2.1. Dotatate
6.3.1.2.2. Dotatoc
6.3.1.2.3. PSMA-11
6.3.1.3. Technetium-99m (Tc-99)
6.3.1.4. Iodine-123 (I-123)
6.3.1.5. Others
6.3.2. Therapy
6.3.2.1. Iodine-131 (I-131)
6.3.2.2. Yttrium-90 (Y-90)
6.3.2.3. Lutetium-177 (Lu-177)
6.3.2.3.1. Lu-PSMA-617
6.3.2.3.2. Lu-DOTA-TATE
6.3.2.4. Others
6.4. Market Attractiveness Analysis, by Radioisotopes
7. Global Radiopharmaceuticals Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2020 to 2035
7.3.1. Oncology
7.3.1.1. Prostate Cancer
7.3.1.2. Breast Cancer
7.3.1.3. Neuroendocrine Tumors
7.3.1.4. Thyroid Cancer
7.3.1.5. Colorectal Cancer
7.3.1.6. Liver Cancer
7.3.1.7. Others
7.3.2. Neurology
7.3.2.1. Alzheimer's Disease
7.3.2.2. Parkinson's Disease
7.3.2.3. Others
7.3.3. Cardiology
7.3.4. Others
7.4. Market Attractiveness Analysis, by Application
8. Global Radiopharmaceuticals Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2020 to 2035
8.3.1. Hospitals
8.3.2. Diagnostics and Imaging Centers
8.3.3. Others
8.4. Market Attractiveness Analysis, by End-user
9. Global Radiopharmaceuticals Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020 to 2035
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Radiopharmaceuticals Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Radioisotopes, 2020 to 2035
10.2.1. Diagnostics
10.2.1.1. Fluorine-18 (F-18)
10.2.1.1.1. Fludeoxyglucose (FDG)
10.2.1.1.2. Sodium Fluoride
10.2.1.1.3. Flucicovine
10.2.1.1.4. Florbetapir
10.2.1.1.5. Florbetaben
10.2.1.1.6. Others
10.2.1.2. Gallium-68 (Ga-68)
10.2.1.2.1. Dotatate
10.2.1.2.2. Dotatoc
10.2.1.2.3. PSMA-11
10.2.1.3. Technetium-99m (Tc-99)
10.2.1.4. Iodine-123 (I-123)
10.2.1.5. Others
10.2.2. Therapy
10.2.2.1. Iodine-131 (I-131)
10.2.2.2. Yttrium-90 (Y-90)
10.2.2.3. Lutetium-177 (Lu-177)
10.2.2.3.1. Lu-PSMA-617
10.2.2.3.2. Lu-DOTA-TATE
10.2.2.4. Others
10.3. Market Value Forecast, by Application, 2020 to 2035
10.3.1. Oncology
10.3.1.1. Prostate Cancer
10.3.1.2. Breast Cancer
10.3.1.3. Neuroendocrine Tumors
10.3.1.4. Thyroid Cancer
10.3.1.5. Colorectal Cancer
10.3.1.6. Liver Cancer
10.3.1.7. Others
10.3.2. Neurology
10.3.2.1. Alzheimer's Disease
10.3.2.2. Parkinson's Disease
10.3.2.3. Others
10.3.3. Cardiology
10.3.4. Others
10.4. Market Value Forecast, by End-user, 2020 to 2035
10.4.1. Hospitals
10.4.2. Diagnostics and Imaging Centers
10.4.3. Others
10.5. Market Value Forecast, by Country, 2020 to 2035
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Radioisotopes
10.6.2. By Application
10.6.3. By End-user
10.6.4. By Country
11. Europe Radiopharmaceuticals Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Radioisotopes, 2020 to 2035
11.2.1. Diagnostics
11.2.1.1. Fluorine-18 (F-18)
11.2.1.1.1. Fludeoxyglucose (FDG)
11.2.1.1.2. Sodium Fluoride
11.2.1.1.3. Flucicovine
11.2.1.1.4. Florbetapir
11.2.1.1.5. Florbetaben
11.2.1.1.6. Others
11.2.1.2. Gallium-68 (Ga-68)
11.2.1.2.1. Dotatate
11.2.1.2.2. Dotatoc
11.2.1.2.3. PSMA-11
11.2.1.3. Technetium-99m (Tc-99)
11.2.1.4. Iodine-123 (I-123)
11.2.1.5. Others
11.2.2. Therapy
11.2.2.1. Iodine-131 (I-131)
11.2.2.2. Yttrium-90 (Y-90)
11.2.2.3. Lutetium-177 (Lu-177)
11.2.2.3.1. Lu-PSMA-617
11.2.2.3.2. Lu-DOTA-TATE
11.2.2.4. Others
11.3. Market Value Forecast, by Application, 2020 to 2035
11.3.1. Oncology
11.3.1.1. Prostate Cancer
11.3.1.2. Breast Cancer
11.3.1.3. Neuroendocrine Tumors
11.3.1.4. Thyroid Cancer
11.3.1.5. Colorectal Cancer
11.3.1.6. Liver Cancer
11.3.1.7. Others
11.3.2. Neurology
11.3.2.1. Alzheimer's Disease
11.3.2.2. Parkinson's Disease
11.3.2.3. Others
11.3.3. Cardiology
11.3.4. Others
11.4. Market Value Forecast, by End-user, 2020 to 2035
11.4.1. Hospitals
11.4.2. Diagnostics and Imaging Centers
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2020 to 2035
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Switzerland
11.5.7. The Netherlands
11.5.8. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Radioisotopes
11.6.2. By Application
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Radiopharmaceuticals Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Radioisotopes, 2020 to 2035
12.2.1. Diagnostics
12.2.1.1. Fluorine-18 (F-18)
12.2.1.1.1. Fludeoxyglucose (FDG)
12.2.1.1.2. Sodium Fluoride
12.2.1.1.3. Flucicovine
12.2.1.1.4. Florbetapir
12.2.1.1.5. Florbetaben
12.2.1.1.6. Others
12.2.1.2. Gallium-68 (Ga-68)
12.2.1.2.1. Dotatate
12.2.1.2.2. Dotatoc
12.2.1.2.3. PSMA-11
12.2.1.3. Technetium-99m (Tc-99)
12.2.1.4. Iodine-123 (I-123)
12.2.1.5. Others
12.2.2. Therapy
12.2.2.1. Iodine-131 (I-131)
12.2.2.2. Yttrium-90 (Y-90)
12.2.2.3. Lutetium-177 (Lu-177)
12.2.2.3.1. Lu-PSMA-617
12.2.2.3.2. Lu-DOTA-TATE
12.2.2.4. Others
12.3. Market Value Forecast, by Application, 2020 to 2035
12.3.1. Oncology
12.3.1.1. Prostate Cancer
12.3.1.2. Breast Cancer
12.3.1.3. Neuroendocrine Tumors
12.3.1.4. Thyroid Cancer
12.3.1.5. Colorectal Cancer
12.3.1.6. Liver Cancer
12.3.1.7. Others
12.3.2. Neurology
12.3.2.1. Alzheimer's Disease
12.3.2.2. Parkinson's Disease
12.3.2.3. Others
12.3.3. Cardiology
12.3.4. Others
12.4. Market Value Forecast, by End-user, 2020 to 2035
12.4.1. Hospitals
12.4.2. Diagnostics and Imaging Centers
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2020 to 2035
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. South Korea
12.5.5. Australia & Newzealend
12.5.6. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Radioisotopes
12.6.2. By Application
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Radiopharmaceuticals Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Radioisotopes, 2020 to 2035
13.2.1. Diagnostics
13.2.1.1. Fluorine-18 (F-18)
13.2.1.1.1. Fludeoxyglucose (FDG)
13.2.1.1.2. Sodium Fluoride
13.2.1.1.3. Flucicovine
13.2.1.1.4. Florbetapir
13.2.1.1.5. Florbetaben
13.2.1.1.6. Others
13.2.1.2. Gallium-68 (Ga-68)
13.2.1.2.1. Dotatate
13.2.1.2.2. Dotatoc
13.2.1.2.3. PSMA-11
13.2.1.3. Technetium-99m (Tc-99)
13.2.1.4. Iodine-123 (I-123)
13.2.1.5. Others
13.2.2. Therapy
13.2.2.1. Iodine-131 (I-131)
13.2.2.2. Yttrium-90 (Y-90)
13.2.2.3. Lutetium-177 (Lu-177)
13.2.2.3.1. Lu-PSMA-617
13.2.2.3.2. Lu-DOTA-TATE
13.2.2.4. Others
13.3. Market Value Forecast, by Application, 2020 to 2035
13.3.1. Oncology
13.3.1.1. Prostate Cancer
13.3.1.2. Breast Cancer
13.3.1.3. Neuroendocrine Tumors
13.3.1.4. Thyroid Cancer
13.3.1.5. Colorectal Cancer
13.3.1.6. Liver Cancer
13.3.1.7. Others
13.3.2. Neurology
13.3.2.1. Alzheimer's Disease
13.3.2.2. Parkinson's Disease
13.3.2.3. Others
13.3.3. Cardiology
13.3.4. Others
13.4. Market Value Forecast, by End-user, 2020 to 2035
13.4.1. Hospitals
13.4.2. Diagnostics and Imaging Centers
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2020 to 2035
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Argentina
13.5.4. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Radioisotopes
13.6.2. By Application
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Radiopharmaceuticals Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Radioisotopes, 2020 to 2035
14.2.1. Diagnostics
14.2.1.1. Fluorine-18 (F-18)
14.2.1.1.1. Fludeoxyglucose (FDG)
14.2.1.1.2. Sodium Fluoride
14.2.1.1.3. Flucicovine
14.2.1.1.4. Florbetapir
14.2.1.1.5. Florbetaben
14.2.1.1.6. Others
14.2.1.2. Gallium-68 (Ga-68)
14.2.1.2.1. Dotatate
14.2.1.2.2. Dotatoc
14.2.1.2.3. PSMA-11
14.2.1.3. Technetium-99m (Tc-99)
14.2.1.4. Iodine-123 (I-123)
14.2.1.5. Others
14.2.2. Therapy
14.2.2.1. Iodine-131 (I-131)
14.2.2.2. Yttrium-90 (Y-90)
14.2.2.3. Lutetium-177 (Lu-177)
14.2.2.3.1. Lu-PSMA-617
14.2.2.3.2. Lu-DOTA-TATE
14.2.2.4. Others
14.3. Market Value Forecast, by Application, 2020 to 2035
14.3.1. Oncology
14.3.1.1. Prostate Cancer
14.3.1.2. Breast Cancer
14.3.1.3. Neuroendocrine Tumors
14.3.1.4. Thyroid Cancer
14.3.1.5. Colorectal Cancer
14.3.1.6. Liver Cancer
14.3.1.7. Others
14.3.2. Neurology
14.3.2.1. Alzheimer's Disease
14.3.2.2. Parkinson's Disease
14.3.2.3. Others
14.3.3. Cardiology
14.3.4. Others
14.4. Market Value Forecast, by End-user, 2020 to 2035
14.4.1. Hospitals
14.4.2. Diagnostics and Imaging Centers
14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-region, 2020 to 2035
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Radioisotopes
14.6.2. By Application
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2024)
15.3. Company Profiles
15.3.1. Advanced Accelerator Applications
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategies
15.3.1.5. Recent Developments
15.3.2. Bayer AG
15.3.2.1. Company Overview
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. Business Strategies
15.3.2.5. Recent Developments
15.3.3. Eli Lilly and Company
15.3.3.1. Company Overview
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. Business Strategies
15.3.3.5. Recent Developments
15.3.4. GE Healthcare
15.3.4.1. Company Overview
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. Business Strategies
15.3.4.5. Recent Developments
15.3.5. ITM Isotopen Technologien München AG
15.3.5.1. Company Overview
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. Business Strategies
15.3.5.5. Recent Developments
15.3.6. Jubilant Pharma Limited
15.3.6.1. Company Overview
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. Business Strategies
15.3.6.5. Recent Developments
15.3.7. Lantheus Holdings, Inc.
15.3.7.1. Company Overview
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. Business Strategies
15.3.7.5. Recent Developments
15.3.8. Nihon Medi-Physics
15.3.8.1. Company Overview
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. Business Strategies
15.3.8.5. Recent Developments
15.3.9. Siemens Healthineers AG
15.3.9.1. Company Overview
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. Business Strategies
15.3.9.5. Recent Developments
15.3.10. Telix Pharmaceuticals
15.3.10.1. Company Overview
15.3.10.2. Financial Overview
15.3.10.3. Product Portfolio
15.3.10.4. Business Strategies
15.3.10.5. Recent Developments
List of Tables
Table 01: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Radioisotopes, 2020 to 2035
Table 02: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Diagnostics, 2020 to 2035
Table 03: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Fluorine-18 (F-18), 2020 to 2035
Table 04: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Gallium-68 (Ga-68), 2020 to 2035
Table 05: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Therapy, 2020 to 2035
Table 06: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Lutetium-177 (Lu-177), 2020 to 2035
Table 07: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 08: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
Table 09: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Neurology, 2020 to 2035
Table 10: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 11: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Region, 2020 to 2035
Table 12: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, by Country, 2020 to 2035
Table 13: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Radioisotopes, 2020 to 2035
Table 14: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Diagnostics, 2020 to 2035
Table 15: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Fluorine-18 (F-18), 2020 to 2035
Table 16: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Gallium-68 (Ga-68), 2020 to 2035
Table 17: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Therapy, 2020 to 2035
Table 18: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Lutetium-177 (Lu-177), 2020 to 2035
Table 19: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 20: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
Table 21: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Neurology, 2020 to 2035
Table 22: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 23: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020 to 2035
Table 24: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Radioisotopes, 2020 to 2035
Table 25: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Diagnostics, 2020 to 2035
Table 26: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Fluorine-18 (F-18), 2020 to 2035
Table 27: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Gallium-68 (Ga-68), 2020 to 2035
Table 28: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Therapy, 2020 to 2035
Table 29: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Lutetium-177 (Lu-177), 2020 to 2035
Table 30: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 31: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
Table 32: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Neurology, 2020 to 2035
Table 33: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 34: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020 to 2035
Table 35: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Radioisotopes, 2020 to 2035
Table 36: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Diagnostics, 2020 to 2035
Table 37: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Fluorine-18 (F-18), 2020 to 2035
Table 38: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Gallium-68 (Ga-68), 2020 to 2035
Table 39: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Therapy, 2020 to 2035
Table 40: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Lutetium-177 (Lu-177), 2020 to 2035
Table 41: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 42: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
Table 43: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Neurology, 2020 to 2035
Table 44: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 45: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020 to 2035
Table 46: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Radioisotopes, 2020 to 2035
Table 47: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Diagnostics, 2020 to 2035
Table 48: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Fluorine-18 (F-18), 2020 to 2035
Table 49: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Gallium-68 (Ga-68), 2020 to 2035
Table 50: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Therapy, 2020 to 2035
Table 51: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Lutetium-177 (Lu-177), 2020 to 2035
Table 52: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 53: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
Table 54: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Neurology, 2020 to 2035
Table 55: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 56: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020 to 2035
Table 57: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Radioisotopes, 2020 to 2035
Table 58: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Diagnostics, 2020 to 2035
Table 59: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Fluorine-18 (F-18), 2020 to 2035
Table 60: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Gallium-68 (Ga-68), 2020 to 2035
Table 61: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Therapy, 2020 to 2035
Table 62: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Lutetium-177 (Lu-177), 2020 to 2035
Table 63: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 64: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
Table 65: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Neurology, 2020 to 2035
Table 66: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
List of Figures
Figure 01: Global Radiopharmaceuticals Market Value Share Analysis, By Radioisotopes, 2024 and 2035
Figure 02: Global Radiopharmaceuticals Market Attractiveness Analysis, By Radioisotopes, 2025 to 2035
Figure 03: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Diagnostics, 2020 to 2035
Figure 04: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Therapy, 2020 to 2035
Figure 05: Global Radiopharmaceuticals Market Value Share Analysis, By Application, 2024 and 2035
Figure 06: Global Radiopharmaceuticals Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 07: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Oncology, 2020 to 2035
Figure 08: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Neurology, 2020 to 2035
Figure 09: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Cardiology, 2020 to 2035
Figure 10: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 11: Global Radiopharmaceuticals Market Value Share Analysis, By End-user, 2024 and 2035
Figure 12: Global Radiopharmaceuticals Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 13: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Hospitals, 2020 to 2035
Figure 14: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Diagnostics and Imaging Centers, 2020 to 2035
Figure 15: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 16: Global Radiopharmaceuticals Market Value Share Analysis, By Region, 2024 and 2035
Figure 17: Global Radiopharmaceuticals Market Attractiveness Analysis, By Region, 2025 to 2035
Figure 18: North America - Radiopharmaceuticals Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 19: North America - Radiopharmaceuticals Market Value Share Analysis, by Country, 2024 and 2035
Figure 20: North America - Radiopharmaceuticals Market Attractiveness Analysis, by Country, 2025 to 2035
Figure 21: North America - Radiopharmaceuticals Market Value Share Analysis, By Radioisotopes, 2024 and 2035
Figure 22: North America - Radiopharmaceuticals Market Attractiveness Analysis, By Radioisotopes, 2025 to 2035
Figure 23: North America - Radiopharmaceuticals Market Value Share Analysis, By Application, 2024 and 2035
Figure 24: North America - Radiopharmaceuticals Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 25: North America - Radiopharmaceuticals Market Value Share Analysis, By End-user, 2024 and 2035
Figure 26: North America - Radiopharmaceuticals Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 27: Europe - Radiopharmaceuticals Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 28: Europe - Radiopharmaceuticals Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 29: Europe - Radiopharmaceuticals Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 30: Europe Radiopharmaceuticals Market Value Share Analysis, By Radioisotopes, 2024 and 2035
Figure 31: Europe Radiopharmaceuticals Market Attractiveness Analysis, By Radioisotopes, 2025 to 2035
Figure 32: Europe - Radiopharmaceuticals Market Value Share Analysis, By Application, 2024 and 2035
Figure 33: Europe - Radiopharmaceuticals Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 34: Europe - Radiopharmaceuticals Market Value Share Analysis, By End-user, 2024 and 2035
Figure 35: Europe - Radiopharmaceuticals Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 36: Asia Pacific - Radiopharmaceuticals Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 37: Asia Pacific - Radiopharmaceuticals Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 38: Asia Pacific - Radiopharmaceuticals Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 39: Asia Pacific - Radiopharmaceuticals Market Value Share Analysis, By Radioisotopes, 2024 and 2035
Figure 40: Asia Pacific - Radiopharmaceuticals Market Attractiveness Analysis, By Radioisotopes, 2025 to 2035
Figure 41: Asia Pacific - Radiopharmaceuticals Market Value Share Analysis, By Application, 2024 and 2035
Figure 42: Asia Pacific - Radiopharmaceuticals Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 43: Asia Pacific - Radiopharmaceuticals Market Value Share Analysis, By End-user, 2024 and 2035
Figure 44: Asia Pacific - Radiopharmaceuticals Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 45: Latin America - Radiopharmaceuticals Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 46: Latin America - Radiopharmaceuticals Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 47: Latin America - Radiopharmaceuticals Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 48: Latin America - Radiopharmaceuticals Market Value Share Analysis, By Radioisotopes, 2024 and 2035
Figure 49: Latin America - Radiopharmaceuticals Market Attractiveness Analysis, By Radioisotopes, 2025 to 2035
Figure 50: Latin America - Radiopharmaceuticals Market Value Share Analysis, By Application, 2024 and 2035
Figure 51: Latin America - Radiopharmaceuticals Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 52: Latin America - Radiopharmaceuticals Market Value Share Analysis, By End-user, 2024 and 2035
Figure 53: Latin America - Radiopharmaceuticals Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 54: Middle East & Africa - Radiopharmaceuticals Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 55: Middle East & Africa - Radiopharmaceuticals Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 56: Middle East & Africa - Radiopharmaceuticals Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 57: Middle East & Africa - Radiopharmaceuticals Market Value Share Analysis, By Radioisotopes, 2024 and 2035
Figure 58: Middle East & Africa - Radiopharmaceuticals Market Attractiveness Analysis, By Radioisotopes, 2025 to 2035
Figure 59: Middle East & Africa - Radiopharmaceuticals Market Value Share Analysis, By Application, 2024 and 2035
Figure 60: Middle East & Africa - Radiopharmaceuticals Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 61: Middle East & Africa - Radiopharmaceuticals Market Value Share Analysis, By End-user, 2024 and 2035
Figure 62: Middle East & Africa - Radiopharmaceuticals Market Attractiveness Analysis, By End-user, 2025 to 2035
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Radiopharmaceuticals Market